NDAINTRAVENOUSSOLUTION
Approved
Nov 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
SESQUIENT (fosphenytoin sodium) by Hikma is accordingly, its anticonvulsant effects are attributable to phenytoin. Approved for generalized tonic-clonic status epilepticus, prevention, treatment of seizures occurring during neurosurgery. First approved in 2020.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SESQUIENT is a fosphenytoin sodium IV solution approved in 2020 for acute seizure management, including status epilepticus and perioperative seizure prophylaxis. It is a prodrug that converts to phenytoin and works by voltage-dependent blockade of neuronal sodium channels to reduce high-frequency discharges. The IV formulation enables rapid administration in emergency seizure settings.
Peak6.8 years to LOE
SESQUIENT is in peak commercial phase with mature market penetration, but team size likely modest given competitive pressure score of zero and absence of linked job activity.
Mechanism of Action
accordingly, its anticonvulsant effects are attributable to phenytoin. The precise mechanism by which phenytoin exerts its therapeutic effect has not been established but is thought to involve the voltage-dependent blockade of membrane sodium channels resulting in a reduction in sustained…
Indications (3)
Worked on SESQUIENT at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.